Articles

TRANSFORM Primary Analysis and Indirect Comparison of Liso-cel to Axi-cel
Dr Jeremy S. Abramson analyzes data from the primary analysis of the TRANSFORM study and a matching-adjusted indirect comparison of liso-cel to axi-cel for the second-line treatment of primary refractory or early relapsed LBCL. Read More ›

The primary analysis of the TRANSFORM study comparing liso-cel to standard of care in adults with primary refractory or early relapsed LBCL resulted in achievement of key clinical benefit end points. Read More ›

Matching-adjusted indirect comparison of liso-cel to axi-cel utilizing data from the TRANSFORM and ZUMA-7 studies revealed lower odds of key CAR-T‒associated adverse events with liso-cel. Read More ›

Phase 1 results of YTB323 in patients with R/R DLBCL demonstrate durable efficacy with a favorable safety profile, as well as identify the recommended phase 2/3 dose. Read More ›

Data from the CIBMTR registry revealed that advanced age does not impact mortality associated with CAR-T therapy, and that CAR-T therapy is feasible in older adults. Read More ›

Two distinct inflammatory clusters were identified and found to be tightly linked to response and survival of patients with LBCL receiving CAR-T therapy, with validation utilizing an independent cohort. Read More ›


Ribociclib in combination with letrozole induces potent antiproliferative effects in comparison to chemotherapy in patients with HR-positive/HER2-negative breast cancer. Read More ›



Page 10 of 136